The Canadian government has sanctioned a startup to export psychedelic substances to Australia for therapeutic purposes. The health department has authorized Optimi Health Corp. to handle the shipment of pills laced with psilocybin, sourced from magic mushrooms, and MDMA.
The rising demand reaches beyond the local Ontario magic mushrooms. Other countries are learning from Canada’s initiative and are beginning to investigate and approve the use of serotogenic compounds for medical benefits.
You can confidently buy psychedelics online in Canada and unlock your inner potential through trustworthy sources.
[toc]Major Takeaways:
- Vancouver-based startup, Optimi Health, has received a drug establishment license to ship magic mushroom pills to Australia.
- Licensed psychiatrists in Australia are allowed to use magic mushrooms as a treatment for chronic depression.
- The treatment consists of three sessions spread over five to eight weeks, with each session lasting for roughly eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a startup from Vancouver, plans to use its certification to broaden the pharmaceutical arena for psychedelic drugs and secure an early market advantage.
Seven firms have exported psilocybin, MDMA, or both, but only for clinical research. A spokesperson from Canada’s health department could not confirm if these exports were for regular patient use and chose not to reveal the companies due to confidentiality concerns.
This accomplishment places Optimi among a handful of global suppliers, as the existing market is inclined towards medicinal rather than recreational use.
What’s in the Pill?
Although the company hasn’t revealed the exact mushroom variety used in the pill, they do utilize several strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, dedicated to the cultivation, testing, and extraction of its psychedelic mushrooms. This quaint community of about 3,000 individuals is situated three hours east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
It’s projected that 1 in every 5 Australians between the ages of 16 and 85 may encounter a mental health issue. PTSD (post-traumatic stress disorder) may impact 11% of Australians at some stage in their lives, while anxiety disorders are common in 17% of the population.
There are numerous treatment strategies for mental health disorders, but not all are effective for everyone. It can be difficult for patients who do not respond to certain therapies to find a beneficial alternative, potentially increasing their vulnerability.
Understanding the Process
Australia has been a leader in adopting psilocybin, allowing licensed psychiatrists to use this regulated substance in the treatment of PTSD and depression that are resistant to traditional methods.
In a noteworthy step in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and magic mushrooms for therapeutic purposes. The TGA declared these substances safe for use in a medically regulated setting for patients with severe mental health conditions.
This progress has been a turning point for many mental health professionals and researchers. The usage of these substances will be strictly monitored; it’s not as simple as taking a pill and leaving.
The treatment protocol typically consists of three sessions over a span of five to eight weeks. Each session lasts approximately eight hours, with the therapist staying with the patient the entire time.
Canada’s Role in Psilocybin Research
Canada has become a leading center for psilocybin research, greatly expanding our understanding of this substance. Health Canada, together with several institutions, is at the forefront of investigating the therapeutic potential of psilocybin in treating a range of mental health disorders.
Research institutions are no longer required to classify these substances as illegal or rely on unregulated dispensaries or mushroom stores. The government now permits certain institutions to grow mushrooms for research purposes.
The increased availability of substances once deemed harmful enables researchers to deepen their understanding of their potential advantages for many individuals.
A Recurring Trend
The potential of this domain was first acknowledged in the 1950s for managing mental health problems and substance misuse, including alcohol addiction. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer spearheaded this pioneering research at the Weyburn Saskatchewan Mental Hospital. The hospital saw significant progress under the leadership of then-premier Tommy Douglas, who allowed the medical fraternity considerable independence to investigate their medical hypotheses.
Dr. Osmond and Dr. Hoffer undertook investigations with LSD, mescaline, and peyote as potential alternatives to the harsh procedures of electroshock and lobotomy. Their research took an unconventional turn, with the pair suggesting that doctors, nurses, and support staff should experiment with these substances.
Canadian Institutes of Health Research
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research are funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Type of Project | Study Focus | Research Institution | Lead Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in end-of-life situations for patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a deeper understanding of the advantages of controlled substances. It has been facilitated by the Canadian Drugs and Substances Strategy (CDSS), launched by the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The therapy involves three eight-hour sessions with MDMA, spaced one month apart, along with nine 90-minute sessions without the drug. Researchers consider this trial to be of historical importance as it marks the first clinical evaluation of an illicit
This is the first psychedelic substance to be studied in over four decades.
An Overview of Psilocybin
Psilocybin, a naturally occurring psychedelic compound, is found in certain species of mushrooms. When ingested, it is metabolized into psilocin, which in turn stimulates the serotonin 5-HT2a receptors located in the brain’s cortical pyramidal cells, the primary processing centers.
Research is currently being conducted by local authorities on this substance’s potential to aid in the treatment of depression, anxiety, addiction, and end-of-life distress, promoting introspection and spiritual enlightenment.
Why is it Potentially Beneficial for Depression, PTSD, and Beyond?
The active compound targets several areas of the brain, making it a potentially effective treatment for a range of mental disorders. Numerous patients in Canada and Australia have already undergone this therapy, and the reported results are promising, with minor side effects such as temporary anxiety or slightly elevated blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: The substance serves as a partial agonist at serotonin receptors, specifically the 5-HT2A subtype, which plays a significant role in emotional processing and mood regulation.
- Modulation of the Default Mode Network (DMN): The substance reduces activity in the DMN, promoting introspective thinking, decreasing rigid thought patterns, and encouraging emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The substance’s antidepressant effects stem from its influence on the brain’s prefrontal and limbic regions, including the amygdala. In depressive cases, individuals often display reduced emotional responsiveness. The substance enhances the response to positive emotional stimuli in the right amygdala while reducing or normalizing the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: The substance induces feelings of euphoria, interconnectedness, and emotional openness during and following the experience.
- Enhanced Emotional Processing: The psychedelic experience may allow individuals to confront and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that it can bring about enduring positive changes such as bettered well-being, enriched life contentment, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Store?
Wondering how this substance could affect your mental health? Surf through your local magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, fosters creative thinking, and enhances concentration and productivity |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Supports better health and elevates overall life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and focus. Contains a potent mix of clinical-strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
International Recognition of Psilocybin
Canada isn’t the sole country advocating the use of magic mushrooms to address mental health disorders. Countries like Australia are also embracing the therapeutic usage of these hallucinogens for conditions such as depression and PTSD. They are procuring top-quality psychedelic capsules from trustworthy sources. Under proper supervision, patients can significantly improve their life quality. Shroom Shop Canada, a magic mushroom supplier, offers a variety of products, from tablets to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA carry therapeutic potential to enhance mental health. Psilocybin engages with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA cultivates empathy and is effective in PTSD treatment. It exhibits potential in boosting emotional processing and therapeutic results, even though it is classified as a regulated drug.
Is this treatment option available to all Australians?
No. In Australia, a preliminary assessment is required to ascertain if an individual is suitable for usage of the substance. This assessment takes into account various factors such as existing heart ailments, history of psychotic episodes, and more. This treatment is solely accessible to patients who have not responded to conventional therapies for conditions such as depression, anxiety, or PTSD.
What are the implications of Canada exporting mushrooms?
Canada is positioning itself to become a major player in the psychedelic market, akin to its role in the cannabis industry. This could pave the way for an increased number of companies to produce high-quality products. As a result, Canada could potentially lead the hallucinogen market, boost its economy, and ease the access of treatments in other countries. Furthermore, it would discourage other nations from procuring their hallucinogens from illegal dispensaries or suppliers, thereby promoting safety.
Articles That May Interest You:
